Study	Reason for exclusion
ACTRN12613000214730	Intervention undertaken was not considered in our protocol. In this trial, study group underwent therapeutic ultrasound insonation over each maxillary sinus for five minutes. This intervention has not been considered in our protocol. Hence, we excluded this trial.
Di Cicco 2014	Follow‐up period was not adequate for analysis. In this trial, included participants were treated with nasal spray formulation consisting of a 10 mL aqueous solution of 0.2% sodium hyaluronate and 3% tobramycin sulphate for 14 days. They were assessed on the first and 14th day. The minimum period of follow‐up needed to include a trial in this review is 3 months. Hence, we excluded this trial.
IRCT20201009048976N1	Intervention undertaken was not considered in our protocol. In this trial, participants were treated with compound honey syrup. This intervention has not been considered in our protocol. Hence, we excluded this trial.
Lee 2021	Intervention undertaken was not considered in our protocol In this trial, the study group was treated with 10% (v/v) manuka honey (MEDIHONEY®; Derma Sciences; Princeton, NJ) . This intervention has not been considered in our protocol. Hence, we excluded this trial.
Mainz 2011	Follow‐up period was not adequate for analysis. In this trial, included participants were treated with inhaled dornase alfa or normal saline for 28 days. They were assessed on 28th day. After a washout period of another 28 days, they were crossed over to the alternative treatment. The minimum period of follow‐up needed to include a trial in this review in 3 months. Hence, we excluded this trial.
Mainz 2014	Follow‐up period was not adequate for analysis. In this trial, included participants were treated with inhaled dornase alfa or normal saline for 28 days. They were assessed on the 28th day. After a washout period of another 28 days, they were crossed over to the alternative treatment. The minimum period of follow‐up needed to include a trial in this review is 3 months. Hence, we excluded this trial.
Mainz 2016	Follow‐up period was not adequate for analysis. In this trial, included participants were treated with inhaled hypertonic saline (6%) or normal saline for 28 days. They were assessed on the 28th day. After a washout period of another 28 days, they were crossed over to the alternative treatment. The minimum period of follow‐up needed to include a trial in this review is 3 months. Hence, we excluded this trial.
NCT00416182	Trial evaluated the effect of medical interventions on surgical outcomes. In this trial, participants were randomized to receive dornase alfa or placebo via nasal inhalation one week following a nasal surgery, to assess improvement in post‐operative sinusitis symptoms. We have planned to exclude trials evaluating effect of medical interventions on surgical outcomes. Hence, we excluded this trial.
NCT03145051	Follow‐up period was not adequate for analysis. In this trial, included participants were treated with nasal irrigation with Respimer® mineral salts solution for 8 weeks. They were assessed at begining of trial, 4 weeks into treatment and at the end of 8 weeks. The minimum period of follow‐up needed to include a trial in this review is 3 months. Hence, we excluded this trial.
NCT03439865	Follow‐up period was not adequate for analysis. In the protocol of this ongoing trial, participants were planned to be treated with ivacaftor along with standard of care treatment (topical nasal steroid spray and culture‐directed antibiotics) or standard of care alone for 14 days. Outcomes are planned to be assessed on day 1, day 14 and day 30. The minimum period of follow‐up needed to include a trial in this review is 3 months. Hence, we excluded this trial.
Wagner 1999	Methodology of randomisation was not acceptable as per our protocol. Investigators preformed a prospective, randomized, phase I clinical trial by instilling adeno‐associated virus vector ‐ CF transmembrane conductance regulator (AAV‐CFTR) into a maxillary sinus with a surgically‐created antrostomy. The contralateral sinus served as a control. According to our protocol, we planned to exclude trials randomized by the side of the nose. Hence, we excluded this trial.
Wagner 2002	Methodology of randomisation was not acceptable as per our protocol. Investigators performed a phase II double‐blind randomized placebo‐controlled trial by instilling 100,000 replication units of targeted genetics adeno‐associated virus vector – CF (tgAAVCF) into one of the maxillary sinuses. The contralateral maxillary sinus acted as a control. According to our protocol, we planned to exclude trials randomized by the side of the nose. Hence we excluded this trial.

CF: cystic fibrosis